COLY-MYCIN S OTIC Rx
Generic Name and Formulations:
Colistin (as sulfate) 3mg, neomycin (as sulfate) 3.3mg, hydrocortisone acetate 10mg, thonzonium bromide 0.5mg; per mL; otic susp; contains thimerosal.
Indications for COLY-MYCIN S OTIC:
Susceptible infections of the external auditory canal, mastoidectomy, fenestration cavities.
Clean and dry ear. 5 drops (using calibrated dropper), or 4 drops (using dropper bottle) in ear(s) 3 or 4 times daily; max 10 days. May substitute saturated cotton wick moistened every 4 hours; replace at least every 24 hrs.
Clean and dry ear. 4 drops (using calibrated dropper), or 3 drops (using dropper bottle) in ear(s) 3 or 4 times daily; max 10 days. May substitute saturated cotton wick moistened every 4 hours; replace at least every 24 hrs.
Viral infections of the ear (e.g., herpes simplex, vaccinia, varicella).
Perforated eardrum. Chronic otitis media. Reevaluate if no improvement in 1 week. Discontinue if local irritation or sensitization occurs.
Antibiotics + steroid + surfactant.
Susp—5mL (w. dropper)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|